C. Michael Gibson and Carolyn Lam discuss key updates to the European heart failure guidelines and how best to initiate medications to optimize outcomes.

C. Michael Gibson, Jean-Philippe Collet, and Gilles Montalescot and discuss apixiban after TAVI in the Atlantis trial.

C. Michael Gibson and Firas Zahr discuss 30-day outcomes following transfemoral transseptal TMVR.

C. Michael Gibson and Bruno Scheller discuss 1-year outcomes of two parallel RCTs.

Junjie Zhang and C. Michael Gibson discuss 3-year outcomes after IVUS- versus angiography-guided DES implantation.

Gregg Stone and C. Michael Gibson discuss a randomized trial examining interventional treatment of vulnerable plaques.

Robert Byrne and C. Michael Gibson discuss a randomized trial of a thromboresistant Polyzene F-coated stent with 14-day DAPT in high-bleeding-risk patients.

Otavio Berwanger and C. Michael Gibson discuss rivaroxaban versus warfarin in patients with bioprosthetic mitral valves and atrial fibrillation or flutter.

Corrado Tamburino and C. Michael Gibson discuss a randomized trial of two self-expanding TAVR bioprostheses.

Dean Kereiakes and C. Michael Gibson discuss intravascular lithotripsy for the treatment of severe coronary calcification.